{"id":26223,"date":"2023-12-15T13:28:45","date_gmt":"2023-12-15T07:58:45","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26223"},"modified":"2023-12-15T13:28:55","modified_gmt":"2023-12-15T07:58:55","slug":"results-from-a-phase-1-trial-of-bgb-16673","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673","title":{"rendered":"BGB-16673 Breakthrough: A Tolerable Triumph in Rapid Clinical Responses for Relapsed\/Refractory B-Cell Malignancies"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>11th December 2023<\/td><\/tr>
Indications<\/td>Relapsed or Refractory (R\/R) B-Cell Malignancies<\/td><\/tr>
Abstract Number<\/td>4401<\/td><\/tr>
Abstract type<\/td>Poster<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The preliminary results from this ongoing clinical trial, unveiled at the ASH 2023 conference, demonstrated that, among the efficacy evaluable patients (n=28), BGB-16673 produced an overall response rate (ORR) of 57%.<\/strong> Moreover, the outcomes encompassed a diverse spectrum, including one complete response (CR), 13 partial responses (PRs), 1 PR with lymphocytosis (PR-L), and one minor response (MR). Additionally, five patients attained stable disease (SD), while five experienced progressive disease (PD). Two patients opted to discontinue treatment before their initial assessment. Notably, the disease control rate (DCR) reached 75%, and the median time to the first response stood at 2.76 months. These results illuminate the varied and promising landscape of treatment responses in this cohort. Apart from that, BGB-16673 achieved remarkable responses with a well-tolerated safety profile in R\/R B-cell malignancies.<\/p>\n\n\n\n

In the realm of hematologic malignancies, both covalent and non-covalent BTK inhibitors have become a standard-of-care treatment. However, a significant challenge arises as many patients confront disease progression due to acquired resistance mutations during their course of treatment. Offering a ray of hope, the chimeric degradation activating compound BGB-16673 emerges as a promising avenue for overcoming resistance to BTK inhibitors. By engaging with both BTK and E3 ligase, this agent triggers BTK degradation through ubiquitination. Encouragingly, preclinical models demonstrate that BGB-16673 effectively degrades not only wild-type BTK but also known resistant mutant proteins associated with both covalent and noncovalent BTK inhibitors, resulting in notable tumor suppression. This breakthrough presents a potential solution to address challenges posed by acquired resistance in the context of BTK inhibitor therapies.<\/p>\n\n\n\n

KOL Insights<\/strong><\/h2>\n\n\n\n
\n

\u201cPreliminary results demonstrate meaningful clinical responses with a short time to response in heavily pretreated patients with a range of B-cell malignancies. Substantial reductions in BTK protein levels in peripheral blood and tumor tissue were also observed, demonstrating proof-of-concept of a strong, on-target effect.\u201d \u2013Expert Opinion.<\/strong><\/p>\n<\/blockquote>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

The BTK degrader BGB-16673 exhibited excellent tolerability, induced prompt and significant clinical responses, and demonstrated on-target effects among patients grappling with relapsed\/refractory B-cell malignancies. This compelling evidence positions BGB-16673 as a promising and well-received advancement in the treatment landscape for these challenging hematologic conditions.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia (ALL) Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 11th December 2023 Indications Relapsed or Refractory (R\/R) B-Cell Malignancies Abstract Number 4401 Abstract type Poster The preliminary results from this ongoing clinical trial, unveiled at the ASH 2023 conference, demonstrated that, among the efficacy evaluable patients (n=28), BGB-16673 produced an overall response rate (ORR) of 57%. Moreover, the outcomes encompassed […]<\/p>\n","protected":false},"author":6,"featured_media":26240,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21526,21525,21534,21533,102,21554,17543,19905,137,841,927,18921,427],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-26223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-american-society-of-hematology-2023","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-b-cell-malignancies","tag-b-cell-malignancies-market","tag-blood-cancer","tag-blood-diseases","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-hematology","tag-oncology","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nResults from a Phase 1 trial of Bgb-16673 in B-Cell Malignancies<\/title>\n<meta name=\"description\" content=\"First Results from a Phase 1 study of the BTK Degrader Bgb-16673 in Patients (Pts) with R\/R B-Cell Malignancies (BGB-16673-101)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Results from a Phase 1 trial of Bgb-16673 in B-Cell Malignancies\" \/>\n<meta property=\"og:description\" content=\"First Results from a Phase 1 study of the BTK Degrader Bgb-16673 in Patients (Pts) with R\/R B-Cell Malignancies (BGB-16673-101)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-15T07:58:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-15T07:58:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15132545\/phase-1-trial-of-bgb-16673.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Results from a Phase 1 trial of Bgb-16673 in B-Cell Malignancies","description":"First Results from a Phase 1 study of the BTK Degrader Bgb-16673 in Patients (Pts) with R\/R B-Cell Malignancies (BGB-16673-101)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673","og_locale":"en_US","og_type":"article","og_title":"Results from a Phase 1 trial of Bgb-16673 in B-Cell Malignancies","og_description":"First Results from a Phase 1 study of the BTK Degrader Bgb-16673 in Patients (Pts) with R\/R B-Cell Malignancies (BGB-16673-101)","og_url":"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-15T07:58:45+00:00","article_modified_time":"2023-12-15T07:58:55+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15132545\/phase-1-trial-of-bgb-16673.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673","url":"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673","name":"Results from a Phase 1 trial of Bgb-16673 in B-Cell Malignancies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15132545\/phase-1-trial-of-bgb-16673.png","datePublished":"2023-12-15T07:58:45+00:00","dateModified":"2023-12-15T07:58:55+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"First Results from a Phase 1 study of the BTK Degrader Bgb-16673 in Patients (Pts) with R\/R B-Cell Malignancies (BGB-16673-101)","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/results-from-a-phase-1-trial-of-bgb-16673#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15132545\/phase-1-trial-of-bgb-16673.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15132545\/phase-1-trial-of-bgb-16673.png","width":1200,"height":800,"caption":"Phase 1 trial of Bgb-16673"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/15132545\/phase-1-trial-of-bgb-16673-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society Of Hematology 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">B-cell malignancies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">B-Cell Malignancies Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Blood Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">blood diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Oncology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">American Society Of Hematology 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">B-cell malignancies<\/span>","<span class=\"advgb-post-tax-term\">B-Cell Malignancies Market<\/span>","<span class=\"advgb-post-tax-term\">Blood Cancer<\/span>","<span class=\"advgb-post-tax-term\">blood diseases<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 15, 2023","modified":"Updated on Dec 15, 2023"},"absolute_dates_time":{"created":"Posted on Dec 15, 2023 1:28 pm","modified":"Updated on Dec 15, 2023 1:28 pm"},"featured_img_caption":"Phase 1 trial of Bgb-16673","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26223"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26223\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26240"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26223"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26223"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}